ME02854B - Hidrohloridne soli antibiotskog jedinjenja - Google Patents

Hidrohloridne soli antibiotskog jedinjenja

Info

Publication number
ME02854B
ME02854B MEP-2017-133A MEP2017133A ME02854B ME 02854 B ME02854 B ME 02854B ME P2017133 A MEP2017133 A ME P2017133A ME 02854 B ME02854 B ME 02854B
Authority
ME
Montenegro
Prior art keywords
hydrochloride salts
antibiotic compound
antibiotic
compound
hydrochloride
Prior art date
Application number
MEP-2017-133A
Other languages
German (de)
English (en)
French (fr)
Inventor
Weijiang Zhang
Ronnie Cheung
Dimitar Filipov
Jack Green
Junning Lee
Original Assignee
Theravance Biopharma Antibiotics Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Antibiotics Ip Llc filed Critical Theravance Biopharma Antibiotics Ip Llc
Publication of ME02854B publication Critical patent/ME02854B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K9/00Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-2017-133A 2013-03-13 2014-03-06 Hidrohloridne soli antibiotskog jedinjenja ME02854B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779065P 2013-03-13 2013-03-13
PCT/US2014/021064 WO2014158952A1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound
EP14717248.0A EP2968446B1 (en) 2013-03-13 2014-03-06 Hydrochloride salts of an antibiotic compound

Publications (1)

Publication Number Publication Date
ME02854B true ME02854B (me) 2018-04-20

Family

ID=50483481

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-133A ME02854B (me) 2013-03-13 2014-03-06 Hidrohloridne soli antibiotskog jedinjenja

Country Status (32)

Country Link
US (1) US9161990B2 (me)
EP (1) EP2968446B1 (me)
JP (3) JP6482523B2 (me)
KR (1) KR20150126659A (me)
CN (1) CN105120883B (me)
AR (1) AR095044A1 (me)
AU (1) AU2014241481B9 (me)
BR (1) BR112015022716A2 (me)
CA (1) CA2902720A1 (me)
CY (1) CY1119316T1 (me)
DK (1) DK2968446T3 (me)
EA (1) EA027282B1 (me)
ES (1) ES2633964T3 (me)
GE (1) GEP20186874B (me)
HK (1) HK1214524A1 (me)
HR (1) HRP20171188T1 (me)
HU (1) HUE033738T2 (me)
IL (1) IL240663A0 (me)
LT (1) LT2968446T (me)
MD (1) MD4599C1 (me)
ME (1) ME02854B (me)
MX (1) MX361984B (me)
PH (1) PH12015502060A1 (me)
PL (1) PL2968446T3 (me)
PT (1) PT2968446T (me)
RS (1) RS56141B1 (me)
SG (1) SG11201507235YA (me)
SI (1) SI2968446T1 (me)
TW (1) TWI608845B (me)
UA (1) UA115086C2 (me)
WO (1) WO2014158952A1 (me)
ZA (1) ZA201506748B (me)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635958B (zh) * 2015-03-24 2021-06-29 丰益贸易私人有限公司 易位脂肪酸的多元醇酯及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434287A (en) * 1975-02-20 1984-02-28 Ciba-Geigy Corporation Cephalosporin derivatives
AR228726A1 (es) 1978-05-26 1983-04-15 Glaxo Group Ltd Procedimiento para la preparacion del antibiotico(6r,7r)-7-((z)-2-(2-aminotiazol-4-il)-2-(2-carboxiprop-2-oxiimino)acetamido)-3-(1-piridiniometil)cef-3-em-4-carboxilato
US4626534A (en) 1984-07-23 1986-12-02 Eli Lilly And Company Pharmaceutical formulation
DE3801179A1 (de) 1988-01-18 1989-07-27 Hoechst Ag Stabilisierung von cephalosporinderivaten durch trocknung mit einem stabilisator sowie stabile zubereitungsformen mit cephalosporinderivaten
JPH0331449A (ja) 1989-06-27 1991-02-12 Yamaha Corp リードフレーム用Fe―Ni合金
ES2059947T3 (es) 1989-09-30 1994-11-16 Eisai Co Ltd Preparados inyectables que contienen cefalosporina y utilizacion de los mismos.
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
TWI335332B (en) * 2001-10-12 2011-01-01 Theravance Inc Cross-linked vancomycin-cephalosporin antibiotics
ATE473986T1 (de) 2003-04-16 2010-07-15 Sandoz Ag Verfahren zur herstellung von cefepim
WO2004113350A1 (en) 2003-05-23 2004-12-29 Theravance, Inc. Cross-linked glycopeptide - cephalosporin antibiotics
US6878868B2 (en) 2003-06-24 2005-04-12 Mcmillan Stacy L. Portable high-hat device
JP4555823B2 (ja) 2003-07-11 2010-10-06 セラヴァンス, インコーポレーテッド 架橋されたグリコペプチド−セファロスポリン抗生物質
TWI342312B (en) 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
EP1656930A1 (en) 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20080103121A1 (en) 2006-10-30 2008-05-01 Gole Dilip J Cephalosporin derivative formulation
FR2932177B1 (fr) 2008-06-06 2012-11-30 Inst Francais Du Petrole Procede d'hydrogenation selective sur un catalyseur contenant de l'or.
JP2010105965A (ja) 2008-10-30 2010-05-13 Taiyo Yakuhin Kogyo Kk バンコマイシン製剤
US8431539B2 (en) 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Also Published As

Publication number Publication date
DK2968446T3 (en) 2017-08-28
GEP20186874B (en) 2018-06-25
PT2968446T (pt) 2017-07-27
WO2014158952A1 (en) 2014-10-02
ZA201506748B (en) 2017-08-30
CN105120883B (zh) 2017-11-17
MD4599B1 (ro) 2018-11-30
MX361984B (es) 2018-12-19
KR20150126659A (ko) 2015-11-12
LT2968446T (lt) 2017-07-25
PH12015502060A1 (en) 2016-01-25
EP2968446B1 (en) 2017-05-03
HK1214524A1 (zh) 2016-07-29
AU2014241481B2 (en) 2018-02-01
UA115086C2 (uk) 2017-09-11
US9161990B2 (en) 2015-10-20
MD4599C1 (ro) 2019-06-30
US20140274877A1 (en) 2014-09-18
AR095044A1 (es) 2015-09-16
AU2014241481B9 (en) 2018-02-15
EP2968446A1 (en) 2016-01-20
MX2015012170A (es) 2015-11-30
TWI608845B (zh) 2017-12-21
AU2014241481A1 (en) 2015-10-01
EA027282B1 (ru) 2017-07-31
CN105120883A (zh) 2015-12-02
JP2017082016A (ja) 2017-05-18
SI2968446T1 (sl) 2017-08-31
PL2968446T3 (pl) 2017-11-30
MD20150101A2 (ro) 2016-02-29
EA201591697A1 (ru) 2016-02-29
TW201444572A (zh) 2014-12-01
SG11201507235YA (en) 2015-10-29
BR112015022716A2 (pt) 2017-07-18
JP6482523B2 (ja) 2019-03-13
CY1119316T1 (el) 2018-02-14
JP2018177817A (ja) 2018-11-15
JP2016513642A (ja) 2016-05-16
ES2633964T3 (es) 2017-09-26
HUE033738T2 (hu) 2018-01-29
RS56141B1 (sr) 2017-10-31
IL240663A0 (en) 2015-10-29
HRP20171188T1 (hr) 2017-10-06
CA2902720A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
HK1224298A1 (zh) 晶體溴結構域抑制劑
HK1213261A1 (zh) 抑制化合物
IL244787A0 (en) Hydrochloride salt form for ezh2 inhibition
EP2982666A4 (en) HETEROCYCLIC COMPOUND
EP3018126A4 (en) HETEROCYCLIC COMPOUND
EP3006444A4 (en) HETEROCYCLIC AMIDE COMPOUND
EP2980089A4 (en) HETEROCYCLIC CONNECTION
EP2989090A4 (en) Polymorphic forms of nilotinib hydrochloride
HRP20190133T1 (hr) Heterociklički spoj
EP2982670A4 (en) HETEROCYCLIC COMPOUND
HK1220187A1 (zh) 抗焦慮化合物的晶型
IL241962B (en) Heterocyclic acetamide compound
HK1220458A1 (zh) 化合物之多晶型物及鹽
HRP20171188T1 (hr) Hidrokloridne soli antibiotskog spoja